This is poised to be the best year on record for Pfizer. They're expecting over a hundred billion in revenue and more than half of that is coming from the COVID-19 vaccine and its pill. But there are a lot of questions as to whether or not any of those products can reap the same kind of success we've seen with generic competition.
Bloomberg News Legal Reporter Jef Feeley explains why Elon Musk is reviving his original deal to buy Twitter at the price of $54.20 a share. Bloomberg Balance of Power Anchor David Westin discusses Micron's plan for a $100 billion for semiconductor factory in New York. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Riley Griffin provide the details of Riley's Businessweek Magazine story Pfizer Needs to Prove That It’s Ready to Move On From Covid-19. Stewart Glickman, Head of Energy Research at CFRA, talks about investing in energy firms in this inflationary environment. And we Drive to the Close with Sylvia Jablonski, CEO at Defiance ETFs.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.